The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

FOXM1 is a therapeutic target for high-risk multiple myeloma.

Gu C, Yang Y, Sompallae R, Xu H, Tompkins VS, Holman C, Hose D, Goldschmidt H, Tricot G, Zhan F, Janz S. Leukemia. 2016 Apr;30(4):873-82. doi: 10.1038/leu.2015.334. Epub 2015 Dec 9. PMID: 26648534 [PubMed - in process] READ MORE

Posted: April 28, 2016

Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents.

Nathwani N, Larsen JT, Kapoor P. Curr Hematol Malig Rep. 2016 Apr;11(2):127-36. doi: 10.1007/s11899-016-0310-9. Review. PMID: 26893062 [PubMed - in process] READ MORE

Posted: April 28, 2016

Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma.

Lust JA, Lacy MQ, Zeldenrust SR, Witzig TE, Moon-Tasson LL, Dinarello CA, Donovan KA. Am J Hematol. 2016 Mar 6. doi: 10.1002/ajh.24352. [Epub ahead of print] PMID: 26945843 [PubMed - as supplied by publisher] READ MORE

Posted: April 28, 2016

Page 28 of 87« First...1020...2627282930...405060...Last »